Latham & Watkins represented Vesper Medical in the transaction. Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, has signed an agreement to […]
Royal Philips’ Acquisition of Vesper Medial
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in […]
nThrive’s $1.7 Billion Acquisition of TransUnion Healthcare
Latham & Watkins represented TransUnion in the transaction while Sidley advised nThrive. TransUnion (NYSE: TRU) has signed a definitive agreement to sell TransUnion Healthcare, Inc. to […]
Minerva Surgical’s $75 Million Initial Public Offering
Latham & Watkins represented the underwriters in the transaction. Minerva Surgical, Inc. (Minerva Surgical), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), […]
Warby Parker’s Direct Listing
Latham & Watkins represented Warby Parker Inc. in the transaction. Warby Parker Inc. executed its direct listing on the New York Stock Exchange under the ticker symbol […]
Thorne HealthTech’s $70 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions […]
GE Healthcare’s $1.45 Billion Acquisition of BK Medical
Schiff Hardin advised BK Medical on the deal. Latham & Watkins represented Altaris Capital. GE Healthcare has entered into an agreement to acquire BK Medical, a […]
Procept BioRobotics’ $163.9 Million Initial Public Offering
Latham & Watkins represented PROCEPT in the transaction. PROCEPT BioRobotics Corporation, a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, […]
ZOLL Medical’s $538 Million Acquisition of Itamar Medical
Latham & Watkins and Goldfarb Seligman & Co. represented Itamar Medical in the transaction. Cooley and Gornitzky & Co. advised ZOLL Medical. Itamar™ Medical Ltd. (Nasdaq […]
Ascendis Pharma’s $400 Million ADSs Public Offering
Latham & Watkins and Mazanti-Andersen represented Ascendis Pharma A/S in the transaction. Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of […]
Eliem Therapeutics’ $80 Million Initial Public Offering
Latham & Watkins represented the underwriters in the offering. Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to […]
Icosavax’s $209.3 Million IPO
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its […]